A Kasahara

Summary

Affiliation: Osaka University
Country: Japan

Publications

  1. ncbi Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death
    A Kasahara
    Department of General Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
    J Viral Hepat 11:148-56. 2004
  2. ncbi Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses
    Y Inoue
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita City, Osaka, Japan
    J Viral Hepat 17:336-44. 2010
  3. ncbi Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin
    N Hiramatsu
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka 565 0871, Japan
    J Viral Hepat 16:586-94. 2009
  4. ncbi Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients
    H Tanaka
    Department of Cancer Control and Statistics, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
    Int J Cancer 87:741-9. 2000
  5. ncbi Enhanced ability of regulatory T cells in chronic hepatitis C patients with persistently normal alanine aminotransferase levels than those with active hepatitis
    I Itose
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan
    J Viral Hepat 16:844-52. 2009
  6. ncbi Generation of hepatitis C virus-specific cytotoxic T lymphocytes from healthy individuals with peptide-pulsed dendritic cells
    A Ito
    Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Japan
    J Gastroenterol Hepatol 16:309-16. 2001
  7. ncbi Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance
    K Katayama
    Department of Internal Medicine, Osaka Kouseinenkin Hospital, Yamadaoka, Suita-city, Osaka, Japan
    J Viral Hepat 8:180-5. 2001
  8. ncbi Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma
    T Tatsumi
    Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
    Cancer Res 61:7563-7. 2001
  9. ncbi Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin
    T Oze
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Yamadaoka, Suita, Osaka 565 0871, Japan
    J Viral Hepat 16:578-85. 2009
  10. ncbi Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection
    H Miyatake
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita Shi, Osaka, Japan
    J Viral Hepat 14:404-12. 2007

Collaborators

Detail Information

Publications15

  1. ncbi Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death
    A Kasahara
    Department of General Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
    J Viral Hepat 11:148-56. 2004
    ..Hence interferon treatment improved survival in chronic hepatitis C patients showing a biochemical as well as a virological response by preventing liver-related deaths...
  2. ncbi Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon alpha-2b and ribavirin: reducing drug doses has no impact on rapid and sustained virological responses
    Y Inoue
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, 2 2 Yamadaoka, Suita City, Osaka, Japan
    J Viral Hepat 17:336-44. 2010
    ..9 +/- 0.90 mg/kg/day) showed 100% and 94% of SVR. Hence, RVR served as an important treatment predictor, and drug exposure had no impact on both SVR and RVR in combination therapy for genotype 2 patients...
  3. ncbi Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin
    N Hiramatsu
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka 565 0871, Japan
    J Viral Hepat 16:586-94. 2009
    ....
  4. ncbi Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients
    H Tanaka
    Department of Cancer Control and Statistics, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
    Int J Cancer 87:741-9. 2000
    ....
  5. ncbi Enhanced ability of regulatory T cells in chronic hepatitis C patients with persistently normal alanine aminotransferase levels than those with active hepatitis
    I Itose
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan
    J Viral Hepat 16:844-52. 2009
    ..The frequency of CD4+CD127-CD25-FOXP3+ cells was higher in CH than those in PNALT. Treg are more abundant in HCV-infected patients, and their suppressor ability is more potent in patients with PNALT than in those with active hepatitis...
  6. ncbi Generation of hepatitis C virus-specific cytotoxic T lymphocytes from healthy individuals with peptide-pulsed dendritic cells
    A Ito
    Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Japan
    J Gastroenterol Hepatol 16:309-16. 2001
    ..We were thus able to generate HCV specific CTL from naive precursors with peptide-pulsed DC. CONCLUSIONS: This DC-based system can be used to generate CTL of desired antigen specificity, even from a source with low CTLpf...
  7. ncbi Immunological response to interferon-gamma priming prior to interferon-alpha treatment in refractory chronic hepatitis C in relation to viral clearance
    K Katayama
    Department of Internal Medicine, Osaka Kouseinenkin Hospital, Yamadaoka, Suita-city, Osaka, Japan
    J Viral Hepat 8:180-5. 2001
    ..These findings suggest that priming with IFN-gamma prior to the initiation of IFN-alpha treatment in patients with refractory chronic hepatitis C can modulate the host immune response and this might contribute to viral clearance...
  8. ncbi Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma
    T Tatsumi
    Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Osaka 565-0871, Japan
    Cancer Res 61:7563-7. 2001
    ..This combination of IL-12 and DCs may be useful for suppressing the growth of residual tumor after primary therapy of human HCC...
  9. ncbi Pegylated interferon alpha-2b (Peg-IFN alpha-2b) affects early virologic response dose-dependently in patients with chronic hepatitis C genotype 1 during treatment with Peg-IFN alpha-2b plus ribavirin
    T Oze
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Yamadaoka, Suita, Osaka 565 0871, Japan
    J Viral Hepat 16:578-85. 2009
    ..Thus, maintaining the Peg-IFN dose as high as possible during the first 12 weeks can yield HCV RNA negativity and higher c-EVR rates, leading to better SVR rates in patients with CH-C genotype 1...
  10. ncbi Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection
    H Miyatake
    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita Shi, Osaka, Japan
    J Viral Hepat 14:404-12. 2007
    ..Such DC impairment is restored in vitro by the addition of ribavirin in not all but some patients who cleared HCV by the combination therapy...
  11. ncbi Significance of serum soluble Fas antigen level in chronic hepatitis C patients treated with interferon: relationship to the therapeutic response
    K Ohkawa
    Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Japan
    J Gastroenterol Hepatol 16:1009-14. 2001
    ..0407) and a high serum soluble Fas antigen level (P = 0.0483). CONCLUSIONS: High production levels of soluble Fas antigen may be associated with a poor response to interferon therapy in chronic hepatitis C patients...
  12. ncbi A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C
    Y Sugimoto
    Department of Molecular Therapeutics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
    J Viral Hepat 9:377-84. 2002
    ..9 (1.6-22); 82%vs 44%; P=0.0062]. These findings suggest that a single nucleotide polymorphism of LMP7 gene is one of the important host factors which independently influence the response to IFN in patients with chronic hepatitis C...
  13. ncbi The enzymatic basis for the conversion of nonfucosylated to fucosylated alpha-fetoprotein by acyclic retinoid treatment in human hepatoma cells: activation of alpha1-6 fucosyltransferase
    K Noda
    Department of Biochemistry, Division of Molecular Therapy Science, Osaka University Graduate School of Medicine, Osaka, Japan
    Tumour Biol 23:202-11. 2002
    ....
  14. ncbi [Two-step interferon rebound therapy for refractory chronic hepatitis C]
    M Kato
    Department of Gastroenterology, Osaka National Hospital
    Nippon Rinsho 59:1315-9. 2001
    ..In the year 2000, health insurance covered the additional administration of IFN. The use of TIRT for additional administration may further improve treatment response in patients who do not respond to IFN treatment...
  15. ncbi Role of Fas ligand in apoptosis induced by hepatitis C virus infection
    E Mita
    First Department of Medicine, Osaka University School of Medicine, Japan
    Biochem Biophys Res Commun 204:468-74. 1994
    ..These findings suggest that the Fas ligand-Fas antigen system may play an important role in liver cell injury by hepatitis C virus infection...